Ibrutinib/ibrutinib medical insurance price in 2024
In the domestic market, the original drug of ibrutinib/Ibrutinib is available in the form of capsule preparations and has been successfully included in the reimbursement scope of Class B medical insurance, but reimbursement is limited to patients who meet specific indications. Its common specifications are 140mg*90 capsules, and the price is about 10,000 yuan. Due to different reimbursement ratios in different regions, the price after reimbursement may be slightly different. For specific information, patients can consult the local medical insurance bureau or hospital.
Indications for patients currently eligible for medical insurance reimbursement in China include but are not limited to Treatment of patients with mantle cell lymphoma(MCL) who have received at least one treatment in the past; or Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); or treatment of patients with Waldenstrom's macroglobulinemia (WM). When these patients are treated with ibrutinib, they need to follow the instructions of the doctor and follow the instructions for use and dosage.
Ibrutinib is a small molecule drug that inhibits B cell proliferation and survival by irreversibly binding to the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often hyperactive in B-cell cancers. Therefore, ibrutinib is used to treat this type of cancer. Ibrutinib also binds to the C-terminal Src kinase. These are non-target receptors for BTK inhibitors. Ibrutinib binds to these receptors and inhibits the kinases promoting cell differentiation and growth. During treatment for chronic lymphocytic leukemia, this can lead to many different side effects, such as left atrial enlargement and atrial fibrillation.
However, if a patient is taking ibrutinib while also taking other drugs that may interact with it or cause serious side effects, doctors may adjust the dose based on the specific situation or even interrupt treatment in some cases to ensure the patient's safety.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)